Please assess the completion status of the following clinical trial:

Trial Title: Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~* Subject must be 18 or older and in good health~* Subject must meet the definition of early rheumatoid arthritis (RA) defined by the 1987-revised American College of Rheumatology (ACR) classification criteria and had disease duration of less than 1 year from diagnosis~* Subject must have a Disease Activity Score (DAS28, based on C-reactive protein) greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8 tender joints out of the 68 assessed~* Subject must fulfill at least one of the following three criteria:~  * Rheumatoid factor positive~ * Greater than 1 joint erosion~ * Anti-cyclic citrullinated peptide (CCP) antibody positive.~Exclusion Criteria~* Subject has previously received systemic anti-tumor necrosis factor (TNF) therapy~* Subject has received any biologic or investigational therapy within 6 weeks prior to Baseline~* Subject has been previously treated with more than 2 disease-modifying antirheumatic drugs (DMARDs) or MTX, had been treated with intra-articular or parenteral administration of corticosteroids in preceding 4 weeks, or had undergone joint surgery within the preceding 2 months at joints to be assessed during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADA+MTX/PBO+MTX (Arm 1) (Type: EXPERIMENTAL): Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
- ADA+MTX/ADA+MTX (Arm2) (Type: EXPERIMENTAL): Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
- ADA+MTX/OL ADA+MTX (Arm 3) (Type: EXPERIMENTAL): Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
- PBO+MTX/PBO+MTX (Arm 4) (Type: EXPERIMENTAL): Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
- PBO+MTX/OL ADA+MTX (Arm 5) (Type: EXPERIMENTAL): Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).